The challenge. Medical Greens Announces Development of New T-Hydrocan Medical Cannabis Product Line
LOS ANGELES, CA--(Marketwired - Nov 25, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary Medical Greens announces its newest product, T-Hydrocan™, a new medicinal cannabis product line. While the focus of SK3's Berkeley Bio's endeavors lies in the development of potential treatments for cancer utilizing non-psychoactive elements of the cannabis/hemp plant, as reflected in the recently-announced Dharmanol™ product line, many patients have found considerable benefit from oral administration of THC, the psychoactive element found in the cannabis / hemp plant, when used to treat a wide variety of medical conditions.
A synthetic version of THC, Marinol™ has been available by prescription for many years, and is prescribed to remediate the pain and nausea from cancer and the side effects of radiation and chemotherapy. Interestingly, Marinol™ is routinely prescribed to cancer patients, and those who also have access to similar natural cannabis products greatly prefer the natural products over the synthetic pharmaceuticals.
T-Hydrocan™ tablets contain the psychoactive element THC, as well as the complete array of cannabinoids that are naturally present in the cannabis / hemp plant. In addition to the cannabinoids, T-Hydrocan™ tablets contain a steam-distilled extract of cannabis / hemp, containing the natural terpenes and terpenoids which work synergistically with the cannabinoids.
Several different versions of T-Hydrocan™ will be offered, adjusting the basic T-Hydrocan™ formula for different applications. T-Hydrocan™ Whole-Plant™ will contain psychoactive, decarboxylated THC, as well as the entire array of related medicinal elements found in the cannabis / hemp plant. T-Hydrocan™ Citrolene™ will contain a healthy dose of the terpene d-Limonene, which attaches to the same receptors as do tranquilizers such as Valium and Xanax, adding a natural relaxing element to the medicine. T-Hydrocan -- CBD™ will add an amount of CBD equal to the THC.
The T-Hydrocan™ line of cannabis-based medicinals will be available through the dispensaries and collectives that have partnered with Medical Greens' wholesale managed collectives.
"We are pleased to add this new product to the arsenal of products available through Medical Greens to fight cancer and we look forward to adding many more," said President Artemus Mayor. "We expect this product to contribute significantly to the growth of the Company as it meets this underserved market."
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
LOS ANGELES, CA--(Marketwired - Nov 25, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary Medical Greens announces its newest product, T-Hydrocan™, a new medicinal cannabis product line. While the focus of SK3's Berkeley Bio's endeavors lies in the development of potential treatments for cancer utilizing non-psychoactive elements of the cannabis/hemp plant, as reflected in the recently-announced Dharmanol™ product line, many patients have found considerable benefit from oral administration of THC, the psychoactive element found in the cannabis / hemp plant, when used to treat a wide variety of medical conditions.
A synthetic version of THC, Marinol™ has been available by prescription for many years, and is prescribed to remediate the pain and nausea from cancer and the side effects of radiation and chemotherapy. Interestingly, Marinol™ is routinely prescribed to cancer patients, and those who also have access to similar natural cannabis products greatly prefer the natural products over the synthetic pharmaceuticals.
T-Hydrocan™ tablets contain the psychoactive element THC, as well as the complete array of cannabinoids that are naturally present in the cannabis / hemp plant. In addition to the cannabinoids, T-Hydrocan™ tablets contain a steam-distilled extract of cannabis / hemp, containing the natural terpenes and terpenoids which work synergistically with the cannabinoids.
Several different versions of T-Hydrocan™ will be offered, adjusting the basic T-Hydrocan™ formula for different applications. T-Hydrocan™ Whole-Plant™ will contain psychoactive, decarboxylated THC, as well as the entire array of related medicinal elements found in the cannabis / hemp plant. T-Hydrocan™ Citrolene™ will contain a healthy dose of the terpene d-Limonene, which attaches to the same receptors as do tranquilizers such as Valium and Xanax, adding a natural relaxing element to the medicine. T-Hydrocan -- CBD™ will add an amount of CBD equal to the THC.
The T-Hydrocan™ line of cannabis-based medicinals will be available through the dispensaries and collectives that have partnered with Medical Greens' wholesale managed collectives.
"We are pleased to add this new product to the arsenal of products available through Medical Greens to fight cancer and we look forward to adding many more," said President Artemus Mayor. "We expect this product to contribute significantly to the growth of the Company as it meets this underserved market."
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
